EP4267557A1 - Nouveau procédé de synthèse de composés ncas - Google Patents
Nouveau procédé de synthèse de composés ncasInfo
- Publication number
- EP4267557A1 EP4267557A1 EP21839577.0A EP21839577A EP4267557A1 EP 4267557 A1 EP4267557 A1 EP 4267557A1 EP 21839577 A EP21839577 A EP 21839577A EP 4267557 A1 EP4267557 A1 EP 4267557A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- branched
- linear
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
- C07K1/082—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing phosphorus
Definitions
- the invention relates to a new process for the synthesis of NCAs compounds. It also relates to a novel use of a peptide coupling agent.
- NCAs are chemical derivatives with high added value industrially used in particular in the production of drugs, or polymers. NCAs are, for example, intermediates of choice for the synthesis of peptides under "solvent-free" ecological conditions.
- NCAs compounds are traditionally carried out with phosgene or a phosgene derivative.
- phosgene or a phosgene derivative are problematic and requires special precautions and installations, in particular because of their toxicity and dangerousness.
- this strategy leads to the concomitant formation of HCl, which is difficult to remove from the NCA product, especially during a large-scale process.
- the presence of residual HCl in the NCA product can give rise to side reactions during its use, for example in a polymerization process.
- One of the aims of the invention is to use the reagent propylphosphonic anhydride in the preparation of NCAs compounds.
- One of the aims of the invention is to provide a new process for the synthesis of NCAs compounds, without the concomitant formation of HCl.
- Another object of the invention is to provide a process for the synthesis of NCAs compounds, in the absence of phosgene, or one of its derivatives.
- One of the aims of the invention is to provide NCAs compounds with good chemical and stereochemical purity.
- Another object of the invention is to provide new NCAs compounds. Another object of the invention is to be able to use the NCAs compounds by virtue of their improved chemical purity, in particular as synthesis intermediates in the preparation of a polymer or of an UNCA compound.
- a first object of the present invention is the use of propane-phosphonic acid anhydride for the preparation of an NCA compound, from an ⁇ -amino acid compound N-protected on the amine function at ⁇ by a -C(O)-O-C 1 to C 20 alkyl substituent, linear or branched, in particular by a tert-butyloxycarbonyl group.
- ⁇ -amino acids can be transformed into NCAs compounds, by the action of propylphosphonic anhydride. This transformation thus makes it possible to obtain said NCAs compounds with good yields, and excellent chemical and stereoisomeric purities.
- Figures 1 and 2 attest to the excellent purity with which the NCAs compounds according to the invention are obtained.
- propanephosphonic acid anhydride is meant a molecule whose structure is shown below. It is an anhydride of propylphosphonic acid, which occurs as a cyclic trimer on which propyl groups are attached to phosphorus atoms.
- the reagent is commercially available, under the name T 3 P ® , in 50 w/w% solution in several solvents, such as ethyl acetate, dimethylformamide, toluene, or tetrahydrofuran.
- linear C 1 to C 20 alkyl is meant an alkyl group comprising from 1 to 20 carbon atoms, chosen from: C 1 methyl, C 2 ethyl, C 3 propyl, C 4 butyl, pentyl C 5 , C 6 hexyl, C 7 heptyl, C 8 octyl, C 9 nonyl, C 10 decyl, C 11 undecyl, C 12 dodecyl, C 13 tridecyl, C 14 tetradecyl, C 15 pentadecyl, C 16 hexadecyl, C 17 heptadecyl, C 18 octadecyl, C 19 nonadecyl, C 20 eicosyl, in particular a linear C 1 to C alkyl group 10 , in particular a linear C 1 to C 5 alkyl group.
- branched alkyl it is necessary to understand a linear alkyl group as defined above comprising substituents chosen from the linear alkyl groups defined above, said linear alkyl groups also being capable of being branched.
- branched alkyl groups mention may in particular be made of an iso-propyl, sec-butyl, iso-butyl, tert-butyl, sec-pentyl, iso-pentyl, iso-hexyl, iso-heptyl, iso-octyl, iso-nonyl group. and isodecyl.
- NCAs ⁇ -Amino Acid N-CarboxyAnhydrides
- ⁇ -Amino Acid N-CarboxyAnhydrides have compounds comprising the motif shown below. These compounds can carry one or more substituents on the carbon in ⁇ of the carbonyl function, as well as on the nitrogen atom.
- these NCAs compounds are prepared from an N-protected ⁇ -amino acid compound comprising a unit represented below, and in which R represents a C 1 to C 20 alkyl group, linear or branched.
- the group R is preferably a tert-butyl group, giving rise to an N-protected acid- ⁇ -amino compound whose amine function at ⁇ is protected by a Boc group.
- the carboxylic acid function present in the aforementioned N-protected ⁇ -amino acid compound is optionally in the carboxylate form, in particular in the form of a sodium salt, a potassium salt, or a lithium salt.
- NCAs compounds A specific class of NCAs compounds are UNCAs, or N-Urethane-CarboxyAnhydrides of ⁇ -amino acids. These compounds contain, on the nitrogen atom of the NCA ring, a urethane group. UNCAs compounds, like other NCAs compounds, can include additional substituents on the carbon of the NCA ring.
- the present invention also makes it possible to obtain this specific class of NCAs compounds. It is appropriate in this case, to use an ⁇ -amino acid doubly N-protected on the amine function at a, in the form of dicarbamate.
- an ⁇ -amino acid N-(Boc) 2 , N-(Boc)(Cbz) or N-(Boc)(Fmoc) can for example be used.
- the present invention relates to a use as defined above, in which the preparation of the compound NCA is carried out:
- the preparation of an NCA compound, from an N-protected ⁇ -amino acid compound, according to the present invention is preferably carried out in the presence of an organic base, said base being capable of promoting the reaction.
- the reaction also takes place in the absence of an organic base, but it is slower. In this case, it would be appropriate to heat the reaction medium, in order to increase the kinetics of the reaction, and to obtain reaction times compatible with an industrial process.
- the reaction takes place at "room temperature”, that is to say at a temperature of between 20 and 30°C, in particular around 25°C.
- the present invention relates to a use as defined above, in which the organic base is a nitrogenous base, in particular chosen from triethylamine, 1,8-diazabicyclo[5.4.0]undec- 7-ene, diisopropylethylamine, N-dimethylaminopyridine, N-methylmorpholine or pyridine, preferably pyridine.
- a nitrogenous base in particular chosen from triethylamine, 1,8-diazabicyclo[5.4.0]undec- 7-ene, diisopropylethylamine, N-dimethylaminopyridine, N-methylmorpholine or pyridine, preferably pyridine.
- the present invention relates to a use as defined above, in which the preparation of the compound NCA is carried out: • either in the presence of an organic base, at room temperature, said organic base being chosen in particular from triethylamine, 1,8-diazabicyclo[5.4.0]undec-7-ene, diisopropylethylamine, N-dimethylaminopyridine, N-methylmorpholine or pyridine,
- the present invention relates to a use as defined above, in which the preparation of the NCA compound is carried out in the presence of an organic solvent.
- organic solvents which can be used in the preparation of an NCA compound, according to the present invention, mention may be made, in a non-limiting manner, of ethyl acetate, butyl acetate, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, N,N-dimethylformamide, chlorobenzene, methylene chloride or acetonitrile.
- the organic solvent is chosen in particular according to the commercial availability of the propane-phosphonic acid anhydride reagent, which is in particular marketed in a 50% solution in ethyl acetate, or dimethylformamide.
- the present invention therefore relates to a use as defined above, in which the organic solvent is chosen from ethyl acetate or dimethylformamide, in particular ethyl acetate.
- the present invention relates to a use as defined above, in which the propane-phosphonic acid anhydride is used in a proportion of 1 to 4 molar equivalents with respect to the acid- ⁇ compound -N-protected amino.
- the quantity of propane-phosphonic acid anhydride is in particular 1, 2, or 3 equivalents, in the presence of an organic base, and in particular 2, 3 or 4 equivalents in the absence of an organic base.
- the present invention relates to a use as defined above, in which the preparation of the NCA compound is carried out in the presence of an organic base at a rate of 0.25 to 3 molar equivalents relative to the N-protected ⁇ -amino acid compound, in particular from 1 to 3 molar equivalents, preferably from 3 molar equivalents.
- from 0.25 to 3 molar equivalents also means the following ranges: from 0.25 to 2, from 0.25 to 1, from 0.25 to 0.5, from 0.5 to 3, from 1 to 2, or from 0.5 to 2.
- the present invention relates to a use as defined above, in which:
- the preparation of the NCA compound is carried out in the presence of an organic solvent, chosen in particular from ethyl acetate or dimethylformamide, and/or
- propane-phosphonic acid anhydride is used at a rate of 1 to 4 molar equivalents relative to the N-protected ⁇ -amino acid compound.
- An amount of less than 1 equivalent of base, relative to the N-protected ⁇ -amino acid compound, can be used.
- a stoichiometric quantity, or greater than the stoichiometric value, of organic base makes it possible to increase the kinetics of the reaction, in order to be able to reach reaction times compatible with an industrial process.
- the present invention relates to a use as defined above, in which the NCA compound is of Formula 1: in which :
- R 1 and R 2 independently represent:
- heteroaryl in which the heteroatom is chosen in particular from N, O, and S, in particular 3-methylindole
- ⁇ C 1 to C 20 -alkyl-heteroaryl in which the heteroatom is chosen in particular from N, O, and S,
- halogen in particular a fluorine atom
- said alkyl, alkyl-aryl or alkyl-heteroaryl possibly being substituted on at least one carbon of the alkyl radical by one or more groups chosen from:
- R 4 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular chosen from tBDMS, t-butyl, benzyl, trityl and xanthyl ,
- R 5 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl and C 1 -C 20 -alkyl-heteroaryl,
- R 6 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl and C 1 -C 20 -alkyl-heteroaryl,
- R 7 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl and C 1 -C 20 -alkyl-heteroaryl,
- R 8 and R 9 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl , C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl and C 1 -C 20 -alkyl-heteroaryl,
- R 10 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, heterocycloalkyl C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular NO 2 , Pbf, Pmc, Mtr or Boc,
- R 11 and R 12 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C cycloalkyl 3 to C 10 , C 3 to C 10 heterocycloalkyl, aryl, C 1 to C 20 -linear or branched alkyl-aryl, heteroaryl, C 1 to C 20 -linear or branched C 1 to C 20 -alkyl-heteroaryl, O-C 1 to C 20 linear or branched, C 1 to C 20 -O-alkyl-aryl linear or branched, the -C(O)R 12 radical being in particular a protective group such as Boc, Cbz, Alloc or Fmoc,
- R 13 and R 14 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, cycloalkyl C 3 to C 10 , C 3 to C 10 heterocycloalkyl, aryl, C 1 to C 20 -alkyl-aryl, heteroaryl and C 1 to C 20 -alkyl-heteroaryl, ⁇ SR 15 , in which R 15 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular trityl or acetamidomethyl (Acm),
- a halogen in particular chosen from F, Cl, Br and I, said aryl, alkyl-aryl, heteroaryl and alkyl-heteroaryl possibly being substituted on the aromatic or heteroaromatic ring by one or more groups chosen from:
- R 16 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular chosen from tBDMS, t-butyl, benzyl, tntyl and xanthyl ,
- R 17 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl, C 1 -C 20 -alkyl-heteroaryl,
- R 18 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl, C 1 -C 20 -alkyl-heteroaryl,
- R 19 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl, C 1 -C 20 -alkyl-heteroaryl,
- R 20 and R 21 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl , C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl, C 1 -C 20 -alkyl-heteroaryl,
- R 22 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, heterocycloalkyl C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular NO 2 , Pbf, Pmc, Mtr or Boc,
- R 23 and R 24 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C cycloalkyl 3 to C 10 , C 3 to C 10 heterocycloalkyl, aryl, C 1 to C 20 -linear or branched alkyl-aryl, heteroaryl, C 1 to C 20 -linear or branched C 1 to C 20 -alkyl-heteroaryl, O-C 1 to C 20 linear or branched, C 1 to C 20 -O-alkyl-aryl linear or branched, the -C(O)R 24 radical being in particular a protective group such as Boc, Cbz, Alloc or Fmoc,
- R 25 and R 26 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, cycloalkyl C 3 to C 10 , C 3 to C 10 heterocycloalkyl, aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl,
- R 27 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular trityl or acetamidomethyl (Acm),
- ⁇ a halogen chosen in particular from F, Cl, Br and I,
- R 3 represents:
- linear C 2 to C 20 alkenyl group is meant: a linear alkyl chain comprising from two to 20 carbon atoms, comprising one or more carbon-carbon double bond(s). In particular a linear alkyl chain of 3 to 15 carbon atoms, of 3 to 10 carbon atoms, of 5 to 20 carbon atoms, of 10 to 20 carbon atoms, or of 5 to 15 carbon atoms.
- branched alkenyl group is meant an alkenyl group as defined above, comprising substituents chosen from the list of linear alkyl groups defined above, said linear alkyl groups also being able to be branched.
- C 3 to C 10 cycloalkyl group is meant a cycloalkyl group comprising from 3 to 10 carbon atoms, chosen from: C 3 cyclopropyl, C 4 cyclobutyl, C 5 cyclopentyl, C 6 cyclohexyl , cycloheptyl C 7 , C 8 cyclooctyl, C 9 cyclononyl, or C 10 cyclodecyl.
- C 3 to C 10 heterocycloalkyl group is meant a cycloalkyl group comprising from 3 to 10 carbon atoms, and further comprising one or more heteroatoms in the ring, in particular 1 or 2 heteroatom(s).
- aryl denotes an aromatic group comprising 5 to 16 carbon atoms within the aromatic ring, in particular from 6 to 12 carbon atoms, in particular comprising 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 carbon atoms.
- the aryl groups according to the present invention can also be substituted, in particular by one or more substituents chosen from: a linear or branched C 1 to C 10 alkyl group, a linear or branched C 1 to C 10 O-alkyl group.
- Phenyl, anisyl and naphthyl, o-tolyl, m-tolyl, p-tolyl, o-xylyl, m-xylyl, p-xylyl, are examples of aryl groups according to the present invention.
- heteroaryl denotes an aryl group as defined above, comprising atoms other than carbon atoms, in particular N, O or S within the aromatic ring.
- Pyridyl, imidazoyl, indolyl, or fiiranyl are examples of heteroaryl groups according to the present invention.
- R 1 and R 2 capable of forming a ring designates spirocyclic compounds, preferably of 3 to 10 carbon atoms, as follows, for general Formula 3, in which R 3 is as defined above.
- NCAs compounds of Formulas 4, 5 and 6 are specific examples of spirocyclic compounds according to the present invention, respectively comprising a cyclopropyl, cyclopentyl, or cyclohexyl ring.
- the NCA compound comprises a 13 C isotope, or several 13 C isotopes
- said isotope is either on one of the carbonyl functions of the NCA ring, or on the side chain, represented by R 1 and/or R 2 in Formula 1.
- the said isotope(s) is (are) preferably on a non-enolizable position of the NCA ring, or on a non-enolizable position.
- -exchangeable side chain represented by R 1 and/or R 2 in Formula 1.
- the expression "the asymmetric centers of said compound of Formula 1 are of R or S configuration, or a mixture of these configurations” refers to the asymmetric centers formed by the configuration of the R 1 and R 2 groups (Formulas 10 and 11 below ), but also to those optionally present on said R 1 and R 2 groups.
- This situation is illustrated by Formula 12 below, in which the R 1 group is a hydrogen atom, and the R 2 group comprises a racemic asymmetric center.
- the carbon bearing the R 1 and R 2 groups has the S configuration.
- the stereochemistry of NCAs molecules is determined by the stereochemistry of the N-protected ⁇ -amino acid from which the NCA compound is formed.
- the compound of Formula 1 is preferably diastereoisomerically pure, the diastereoisomeric excess being greater than 80%.
- greater than 80% also means greater than 90%, greater than 95%, greater than 98% and in particular greater than 99%.
- the compound of Formula 1 is preferably enantiomerically pure, the enantiomeric excess being greater than 80%, the starting N-protected ⁇ -amino acid being in particular of L configuration.
- the term “greater than 80%” also means greater than 90%, greater than 95%, greater than 98% and in particular greater than 99%.
- the present invention relates to a use as defined above, in which the compound of Formula 1 is such that:
- R 1 and R 2 independently represent:
- heteroaryl in which the heteroatom is chosen in particular from N, O, and S, in particular 3-methylindole,
- alkyl, alkyl-aryl or alkyl-heteroaryl possibly being substituted on at least one carbon of the alkyl radical by one or more groups chosen from:
- R 4 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular chosen from tBDMS, t-butyl, benzyl, trityl and xanthyl ,
- R 8 and R 9 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl , C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl and C 1 -C 20 -alkyl-heteroaryl,
- R 10 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, heterocycloalkyl C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular NO 2 , Pbf, Pmc, Mtr or Boc,
- R 11 and R 12 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C cycloalkyl 3 to C 10 , C 3 to C 10 heterocycloalkyl, aryl, C 1 to C 20 -linear or branched alkyl-aryl, heteroaryl, C 1 to C 20 -linear or branched C 1 to C 20 -alkyl-heteroaryl, O-C 1 to C 20 linear or branched, C 1 to C 20 -O-alkyl-aryl linear or branched, the -C(O)R 12 radical being in particular a protective group such as Boc, Cbz, Alloc or Fmoc,
- R 15 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular trityl or acetamidomethyl (Acm), said aryl, alkyl-aryl, heteroaryl and alkyl-heteroaryl which may be substituted on the aromatic or heteroaromatic ring by one or more groups chosen from:
- R 16 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular chosen from tBDMS, t-butyl, benzyl, trityl and xanthyl ,
- R 20 and R 21 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl , C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl, C 1 -C 20 -alkyl-heteroaryl,
- R 22 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, heterocycloalkyl C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular NO 2 , Pbf, Pmc, Mtr or Boc,
- R 23 and R 24 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C cycloalkyl 3 to C 10 , C 3 to C 10 heterocycloalkyl, aryl, C 1 to C 20 -linear or branched alkyl-aryl, heteroaryl, C 1 to C 20 -linear or branched C 1 to C 20 -alkyl-heteroaryl, O-C 1 to C 20 linear or branched, C 1 to C 20 -O-alkyl-aryl linear or branched, the -C(O)R 24 radical being in particular a protective group such as Boc, Cbz, Alloc or Fmoc,
- R 27 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular trityl or acetamidomethyl (Acm),
- ⁇ a halogen chosen in particular from F, Cl, Br and I,
- R 3 represents:
- the present invention relates to a use as defined above, in which the compound of Formula 1 is such that:
- R 1 and R 2 independently represent:
- heteroaryl in which the heteroatom is chosen in particular from N, O, and S, in particular 3-methylindole, said alkyl or alkyl-aryl possibly being substituted on at least one carbon of the alkyl radical by one or more groups chosen from :
- R 4 is chosen from H, C 1 to C 20 alkyl, linear or branched, and a protective group, in particular chosen from tBDMS, t-butyl, benzyl, tntyl and xanthyl,
- R 8 and R 9 are independently chosen from H, C 1 to C 20 alkyl, linear or branched,
- R 10 is chosen from H, C 1 to C 20 alkyl, linear or branched, and a protective group, in particular Pbf, Pmc, Mtr or Boc,
- R 11 and R 12 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, O-C 1 to C 20 linear or branched alkyl, C 1 at C 20 -O-alkyl- linear or branched aryl, the -C(O)R 12 radical being in particular a protective group such as Boc, Cbz, Alloc or Fmoc,
- R 15 is chosen from H, C 1 to C 20 alkyl, linear or branched, and a protective group, in particular trityl or acetamidomethyl (Acm), said alkyl-aryl or heteroaryl possibly being substituted on the aromatic or heteroaromatic ring by one or more groups chosen from:
- R 16 is chosen from H, C 1 to C 20 alkyl, linear or branched, and a protective group, in particular chosen from tBDMS, t-butyl, benzyl, trityl and xanthyl,
- R 20 and R 21 are independently chosen from H, C 1 to C 20 alkyl, linear or branched,
- R 22 is chosen from H, C 1 to C 20 alkyl, linear or branched, and a protective group, in particular NO 2 , Pbf, Pmc, Mtr or Boc,
- R 23 and R 24 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, O-C 1 to C 20 linear or branched alkyl, C 1 linear or branched C 20 -O-alkylaryl, the -C(O)R 24 radical being in particular a protective group such as Boc, Cbz, Alloc or Fmoc,
- R 27 is chosen from H, C 1 to C 20 alkyl, linear or branched, and a protective group, in particular trityl or acetamidomethyl (Acm),
- R 3 represents:
- the present invention relates to a use as defined above, in which the compound of Formula 1 is such that: R 1 and R 2 independently represent:
- alkyl possibly being substituted by one or more groups chosen from:
- R 10 is chosen from a protective group, in particular NO 2 , Pbf, Pmc, Mtr or Boc,
- R 11 is H
- the -C(O)R 12 radical is a protecting group such as Boc, Cbz, Alloc or Fmoc
- R 3 represents:
- the present invention relates to a use as defined above, in which the compound of Formula 1 is such that R 3 is a hydrogen atom.
- the compound of Formula 1 has the structure of Formula 13: in which R 1 and R 2 are as defined above.
- the present invention relates to a use as defined above, in which the compound of Formula 1 is such that R 1 and R 2 are identical, and are in particular a methyl.
- the present invention relates to a use as defined above, in which the compound of Formula 1 is such that R 1 and R 2 form a cycle.
- the present invention relates to a use as defined above, in which the compound of Formula 1 is such that one of R 1 or R 2 is a hydrogen atom.
- the compound of Formula 1 has the structure of Formula 14, or Formula 14': in which R 1 , R 2 and R 3 are as defined above.
- the present invention relates to a use as defined above, in which at least one of the R 1 or R 2 groups comprises at least one protective group for carboxylic acid functions, amine functions, thiol functions, guanidine functions, amide functions and/or alcohol functions, chosen in particular from tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), fluorenylmethyloxycarbonyl (Fmoc), alloc, tert-butyloxy (OtBu), formyl (For), 2,2,4,6,7-pentamethylhydrobenzofuran-5-sulfonyl (Pbf), 2, 2, 5, 7, 8- pentamethylchroman-6-sulfonyl (Pmc), 4-methoxy-2,3,6-trimethylbenzenesulfonyl ( Mtr), trityl (Trt), trifluoroacetyl, acetamidomethyl (Acm), and x
- the protective groups that can be used according to the present invention are any protective group available to those skilled in the art (Greene's Protective Groups in Organic Synthesis, 4th edition, Wiley).
- the present invention relates to a use as defined above, in which the NCA compound is chosen from: alanine-NCA, arginine-NCA, asparagine-NCA, aspartic acid-NCA, cysteine-NCA, glutamine-NCA, glutamic acid-NCA, glycine-NCA, histidine-NCA, isoleucine-NCA, leucine-NCA, lysine-NCA, methionine-NCA, phenylalanine-NCA, proline-NCA, serine-NCA, threonine-NCA, tryptophan-NCA, tyrosine-NCA, valine-NCA, acid-1,2,3,4 - tetrahydro-isoquinoline-3-carboxylic-NCA
- the present invention also relates to a use as defined above, in which the NCA compound is an UNCA compound, in particular an UNCA compound of the following structure: in which R' is chosen from a C 1 to C 20 alkyl group, linear or branched, in particular a tert-butyl, or an aryl-methyl group, in particular a benzyl group or a fluorenylmethyl group, in which R 1 and R 2 are as defined above.
- the present invention relates to a use as defined above, in which the NCA compound is chosen from the following structures:
- a second object of the present invention is a process for the preparation of an NCA compound, comprising:
- the present invention relates to a method as defined above, in which the contacting step comprises: • a stirring step at a temperature of 40 to 80°C, in the absence of said organic base.
- the present invention relates to a method as defined above, in which the contacting step comprises:
- the method of the present invention can be implemented in a flow chemistry device.
- the present invention therefore relates to a method as defined above, said method being implemented in continuous flow.
- the present invention relates to a method as defined above, further comprising, after obtaining the NCA, a step of purification by at least one aqueous wash.
- the aqueous washing makes it possible in particular to eliminate the propylphosphonic acid formed during the reaction.
- the present invention relates to a method as defined above, further comprising a step of purification of the NCA compound, in particular by recrystallization.
- the present invention relates to a method as defined above, in which the contacting step is carried out for a period of 1 to 24 hours, in particular approximately 2 hours.
- the process according to the present invention generally makes it possible to obtain complete conversion after 2 hours of reaction.
- the reaction time may however be longer if the analysis of an aliquot demonstrates the presence of the starting N-protected ⁇ -amino acid.
- the present invention relates to a method as defined above, in the presence of an organic base, said organic base being a nitrogenous base, chosen in particular from triethyl amine, 1,8-diazabicyclo [5.4.0]undec-7-ene, diisopropylethylamine, N-dimethylaminopyridine, diisopropylethylamine or pyridine, preferably pyridine.
- the present invention relates to a process as defined above, in which the organic solvent is chosen from ethyl acetate or dimethylformamide, in particular ethyl acetate.
- the present invention relates to a process as defined above, in which the propane-phosphonic acid anhydride is used in a proportion of 1 to 4 molar equivalents with respect to the acid- ⁇ compound -N-protected amino, in particular of 2 molar equivalents.
- the present invention relates to a process as defined above, in the presence of an organic base at a rate of 0.25 to 3 molar equivalents with respect to the ⁇ -amino acid compound N- protected, in particular from 1 to 3 molar equivalents, preferably from 3 molar equivalents.
- the present invention relates to a process as defined above, in the presence of an organic base, in which the base is pyndine in an amount of 3 molar equivalents relative to the acid- N-protected ⁇ -amino acid, wherein the propane-phosphonic acid anhydride is used at 2 molar equivalents relative to the N-protected ⁇ -amino acid compound, and wherein the agitation step is performed at room temperature.
- the present invention relates to a process as defined above, in which the propane-phosphonic acid anhydride is used at a rate of 4 molar equivalents with respect to the ⁇ -amino acid compound N-protected, and wherein the stirring step is carried out at a temperature of 50 to 80°C, in the absence of an organic base.
- the present invention relates to a process for the preparation of an NCA compound, as defined above, comprising:
- an N-protected ⁇ -amino acid compound into contact with: propane-phosphonic acid anhydride, and optionally an organic base, in particular a nitrogenous base, in particular chosen from triethylamine, 1,8-diazabicyclo[5.4.0]undec-7-ene, diisopropylethylamine, N-dimethylaminopyridine, diisopropylethylamine or pyridine, preferably pyridine, in an organic solvent, chosen in particular from ethyl acetate or dimethylformamide, to obtain said NCA compound, and optionally:
- an organic base in particular a nitrogenous base, in particular chosen from triethylamine, 1,8-diazabicyclo[5.4.0]undec-7-ene, diisopropylethylamine, N-dimethylaminopyridine, diisopropylethylamine or pyridine, preferably pyridine, in an organic solvent, chosen in particular from ethyl
- the present invention relates to a method for preparing an NCA compound, as defined above, in which the contacting step comprises:
- the present invention relates to a process as defined above, in which said NCA compound is of Formula 1-A, prepared from an N-protected ⁇ -amino acid compound of Formula 2-A, according to the following reaction scheme:
- R 1 and R 2 independently represent:
- ⁇ C 3 to C 10 cycloalkyl ⁇ C 3 to C 10 heterocycloalkyl, in which the heteroatom is chosen in particular from N, O and S,
- heteroaryl in which the heteroatom is chosen in particular from N, O, and S, in particular 3-methylindole,
- halogen in particular a fluorine atom
- said alkyl, alkyl-aryl or alkyl-heteroaryl possibly being substituted on at least one carbon of the alkyl radical by one or more groups chosen from:
- R 4 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular chosen from tBDMS, t-butyl, benzyl, tntyl and xanthyl ,
- R 5 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl and C 1 -C 20 -alkyl-heteroaryl,
- R 6 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl and C 1 -C 20 -alkyl-heteroaryl,
- R 7 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl and C 1 -C 20 -alkyl-heteroaryl,
- R 8 and R 9 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl , C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl and C 1 -C 20 -alkyl-heteroaryl,
- R 10 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, heterocycloalkyl C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular NO 2 , Pbf, Pmc, Mtr or Boc,
- R 11 and R 12 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C cycloalkyl 3 to C 10 , C 3 to C 10 heterocycloalkyl, aryl, C 1 to C 20 -linear or branched alkyl-aryl, heteroaryl, C 1 to C 20 -linear or branched C 1 to C 20 -alkyl-heteroaryl, O-C 1 to C 20 linear or branched, C 1 to C 20 -O-alkyl-aryl linear or branched, the -C(O)R 12 radical being in particular a protective group such as Boc, Cbz, Alloc or Fmoc,
- R 13 and R 14 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, cycloalkyl C 3 to C 10 , C 3 to C 10 heterocycloalkyl, aryl, C 1 to C 20 -alkyl-aryl, heteroaryl and C 1 to C 20 -alkyl-heteroaryl,
- R 15 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular trityl or acetamidomethyl (Acm),
- a halogen in particular chosen from F, Cl, Br and I, said aryl, alkyl-aryl, heteroaryl and alkyl-heteroaryl possibly being substituted on the aromatic or heteroaromatic ring by one or more groups chosen from:
- R 16 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular chosen from tBDMS, t-butyl, benzyl, trityl and xanthyl ,
- R 17 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl, C 1 -C 20 -alkyl-heteroaryl,
- R 18 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl, C 1 -C 20 -alkyl-heteroaryl,
- R 19 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl, C 1 -C 20 -alkyl-heteroaryl,
- R 20 and R 21 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl , C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl, C 1 -C 20 -alkyl-heteroaryl,
- R 22 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, heterocycloalkyl C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular NO 2 , Pbf, Pmc, Mtr or Boc,
- R 23 and R 24 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C cycloalkyl 3 to C 10 , C 3 to C 10 heterocycloalkyl, aryl, C 1 to C 20 -linear or branched alkyl-aryl, heteroaryl, C 1 to C 20 -linear or branched C 1 to C 20 -alkyl-heteroaryl, O-C 1 to C 20 linear or branched, C 1 to C 20 -O-alkyl-aryl linear or branched, the -C(O)R 24 radical being in particular a protective group such as Boc, Cbz, Alloc or Fmoc,
- R 25 and R 26 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, cycloalkyl C 3 to C 10 , C 3 to C 10 heterocycloalkyl, aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl,
- R 27 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular tntyl or acetamidomethyl (Acm),
- ⁇ a halogen chosen in particular from F, Cl, Br and I,
- R 3 represents:
- the compound of Formula 1-A, or the compound of Formula 2-A comprises a carbon atom
- said carbon atom may be 13 C
- said fluorine atom may be 18 F
- said hydrogen atom may be deuterium
- the asymmetric centers of said compound of Formula 1-A, and of said compound of Formula 2-A are of R or S configuration, or a mixture of these configurations.
- the carboxylic acid function present in the compound of Formula 2-A is optionally in the carboxylate form, in particular in the form of a sodium salt, a potassium salt, or a lithium salt.
- the present invention relates to a process as defined above, in which the compound of Formula 1-A and the compound of Formula 2-A are such that:
- R 1 and R 2 independently represent:
- heteroaryl in which the heteroatom is chosen in particular from N, O, and S, in particular 3-methylindole,
- alkyl, alkyl-aryl or alkyl-heteroaryl possibly being substituted on at least one carbon of the alkyl radical by one or more groups chosen from:
- R 4 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular chosen from tBDMS, t-butyl, benzyl, trityl and xanthyl ,
- R 8 and R 9 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl , C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl and C 1 -C 20 -alkyl-heteroaryl,
- R 10 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, heterocycloalkyl C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular NO 2 , Pbf, Pmc, Mtr or Boc,
- R 11 and R 12 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C cycloalkyl 3 to C 10 , C 3 to C 10 heterocycloalkyl, aryl, C 1 to C 20 -linear or branched alkyl-aryl, heteroaryl, C 1 to C 20 -linear or branched C 1 to C 20 -alkyl-heteroaryl, O-C 1 to C 20 linear or branched, C 1 to C 20 -O-alkyl-aryl linear or branched, the -C(O)R 12 radical being in particular a protective group such as Boc, Cbz, Alloc or Fmoc,
- R 15 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 10 -alkyl-heteroaryl and a protective group, in particular trityl or acetamidomethyl (Acm), said aryl, alkyl-aryl, heteroaryl and alkyl-heteroaryl which may be substituted on the aromatic or heteroaromatic ring by one or more groups chosen from:
- R 16 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, C 3 to C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular chosen from tBDMS, t-butyl, benzyl, trityl and xanthyl ,
- R 20 and R 21 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl , C 3 -C 10 heterocycloalkyl, aryl, C 1 -C 20 -alkyl-aryl, heteroaryl, C 1 -C 20 -alkyl-heteroaryl,
- R 22 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, heterocycloalkyl C 3 to C 10 , aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular NO 2 , Pbf, Pmc, Mtr or Boc,
- R 23 and R 24 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C cycloalkyl 3 to C 10 , C 3 to C 10 heterocycloalkyl, aryl, C 1 to C 20 -linear or branched alkyl-aryl, heteroaryl, C 1 to C 20 -linear or branched C 1 to C 20 -alkyl-heteroaryl, O-C 1 to C 20 linear or branched, C 1 to C 20 -O-alkyl-aryl linear or branched, the -C(O)R 24 radical being in particular a protective group such as Boc, Cbz, Alloc or Fmoc,
- R 27 is chosen from H, C 1 to C 20 alkyl, linear or branched, C 1 to C 20 heteroalkyl, linear or branched, C 3 to C 10 cycloalkyl, heterocycloalkyl C 3 to C 10 aryl, C 1 to C 20 -alkyl-aryl, heteroaryl, C 1 to C 20 -alkyl-heteroaryl and a protective group, in particular trityl or acetamidom ethyl (Acm),
- ⁇ a halogen chosen in particular from F, Cl, Br and I,
- R 3 represents:
- R 33 represents a linear or branched C 1 to C 20 alkyl group, in particular a tert-butyl, said compound of Formula 1-A possibly being in the form of a solvate or a hydrate, said NR 8 R groups 9 .
- the present invention relates to a process as defined above, in which the compound of Formula 1-A and the compound of Formula 2-A are such that:
- R 1 and R 2 independently represent:
- heteroaryl in which the heteroatom is chosen in particular from N, O, and S, in particular 3-methylindole, said alkyl or alkyl-aryl possibly being substituted on at least one carbon of the alkyl radical by one or more groups chosen from:
- R 4 is chosen from H, C 1 to C 20 alkyl, linear or branched, and a protective group, in particular chosen from tBDMS, t-butyl, benzyl, trityl and xanthyl,
- R 8 and R 9 are independently chosen from H, C 1 to C 20 alkyl, linear or branched,
- R 10 is chosen from H, C 1 to C 20 alkyl, linear or branched, and a protective group, in particular NO 2 , Pbf, Pmc, Mtr or Boc,
- R 11 and R 12 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, O-C 1 to C 20 linear or branched alkyl, C 1 linear or branched C 20 -O-alkylaryl, the -C(O)R 12 radical being in particular a protective group such as Boc, Cbz, Alloc or Fmoc,
- R 15 is chosen from H, C 1 to C 20 alkyl, linear or branched, and a protective group, in particular tntyl or acetamidomethyl (Acm), said alkyl-aryl or heteroaryl possibly being substituted on the aromatic or heteroaromatic ring by one or more groups chosen from:
- R 16 is chosen from H, C 1 to C 20 alkyl, linear or branched, and a protective group, in particular chosen from tBDMS, t-butyl, benzyl, trityl and xanthyl,
- R 20 and R 21 are independently chosen from H, C 1 to C 20 alkyl, linear or branched,
- R 22 is chosen from H, C 1 to C 20 alkyl, linear or branched, and a protective group, in particular NO 2 , Pbf, Pmc, Mtr or Boc,
- R 23 and R 24 are independently chosen from H, C 1 to C 20 alkyl, linear or branched, O-C 1 to C 20 linear or branched alkyl, C 1 linear or branched C 20 -O-alkylaryl, the -C(O)R 24 radical being in particular a protective group such as Boc, Cbz, Alloc or Fmoc,
- R 27 is chosen from H, C 1 to C 20 alkyl, linear or branched, and a protective group, in particular trityl or acetamidomethyl (Acm),
- R 3 represents:
- R 33 represents a linear or branched C 1 to C 20 alkyl group, in particular a tert-butyl, said compound of Formula 1-A possibly being in the form of a solvate or a hydrate, said NR 8 R groups 9 (NH)CNHR 10 , NR 20 R 21 and (NH)CNHR 22 , and/or heteroaryl of the compound of Formula 1-A possibly being in a salified form, the asymmetric centers of said compound of Formula 1-A, and of said compound of Formula 2-A, are of R or S configuration, or a mixture of these configurations.
- the present invention relates to a process as defined above, in which the compound of Formula 1-A and the compound of Formula 2-A are such that:
- R 1 and R 2 independently represent:
- alkyl possibly being substituted by one or more groups chosen from:
- R 10 is chosen from a protective group, in particular NO 2 , Pbf, Pmc, Mtr or Boc,
- R 11 is H
- the -C(O)R 12 radical is a protecting group such as Boc, Cbz, Alloc or Fmoc
- R 3 represents:
- R 33 represents a tert-butyl group, said compound of Formula 1-A possibly being in the form of a solvate or a hydrate, said NR 8 R 9 , (NH)CNHR 10 , NR 20 R 21 and (NH)CNHR 22 and/or 3-methylindole groups, of the compound of Formula 1 -A possibly being in a salified form, the asymmetric centers of said compound of Formula 1-A, and said compound of Formula 2-A, are of R or S configuration, or a mixture of these configurations.
- the present invention relates to a process as defined above, in which R 3 is a hydrogen atom.
- the present invention relates to a process as defined above, in which R 1 and R 2 are identical, and in particular represent a methyl.
- the present invention relates to a process as defined above, in which one of R 1 or R 2 is a hydrogen atom.
- the present invention relates to a method as defined above, in which R 1 or R 2 form a cycle.
- the present invention relates to a process as defined above, in which at least one of the R 1 or R 2 groups comprises at least one protective group, carboxylic acid functions, amine functions, thiol functions, guanidine functions, amide functions and/or alcohol functions, chosen in particular from tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), fluorenylmethyloxycarbonyl (Fmoc), alloc, tert-butyloxy (OtBu), formyl (For), 2,2,4,6,7-pentamethylhydrobenzofuran-5-sulfonyl (Pbf), 2, 2, 5, 7, 8- pentamethylchroman-6-sulfonyl (Pmc), 4-methoxy-2,3,6-trimethylbenzenesulfonyl ( Mtr), trityl (Trt), trifluoroacetyl, acetamidomethyl (Acm), and x
- the present invention relates to a method as defined above, comprising:
- the present invention relates to a process as defined above, in which the ⁇ -amino acid compound is chosen from: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine isoleucine, leucine, lysine, amethionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, l 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (Tic), 2-amino-2-methylpropanoic acid (Aib), and norleucine (NIe), said acid- ⁇ - amine being N-protected on the amine function at a by a -C(O)-O- C 1 to C 20 alkyl substituent, linear or branched, in particular by a -tert-butyloxycarbonyl group, the said amino acids
- the present invention also relates to a process as defined above, in which the NCA compound is an UNCA compound, in particular an UNCA compound of the following structure: in which R' is chosen from a C 1 to C 20 alkyl group, linear or branched, in particular a tert-butyl, or an aryl-methyl group, in particular a benzyl group or a fluorenylmethyl group, in which R 1 and R 2 are as defined above.
- a third object of the present invention is an NCA compound, as obtained by the process as defined above.
- the process for preparing an NCA compound according to the invention makes it possible to have NCA compounds of excellent purity, and devoid of phosgene decomposition products, of decomposition of diphosgene and decomposition products of triphosgene, in particular devoid of hydrochloric acid.
- the process also makes it possible to avoid the contaminations observed when the NCA compound is prepared under nitrosation conditions.
- NCA compounds can be detrimental in certain uses of NCA compounds, in particular in the synthesis of a peptide, where the presence of hydrochloric acid residues, for example, is troublesome.
- such compounds according to the present invention can be salified, after their isolation, during a salification step in which the NCA compound is placed in the presence of an acid, for example such as hydrochloric acid or triflic acid. , non-nucleophilic.
- an acid for example such as hydrochloric acid or triflic acid.
- non-nucleophilic non-nucleophilic.
- it is the salification of a salifiable function on the side chain, and not the nitrogen of the NCA cycle, the salified forms of which are unstable.
- a fourth object of the present invention is a new NCA compound, chosen from the following structures:
- the invention also relates to a novel NCA compound of the following structure: According to another particular embodiment, the present invention relates to a new NCA compound as defined below, chosen from:
- a fifth object of the present invention is a solution comprising an NCA compound prepared according to the process as defined above, or an NCA compound as defined above, said solution being free of phosgene decomposition products, of decomposition of diphosgene and decomposition products of triphosgene, in particular devoid of hydrochloric acid.
- a sixth object of the present invention is the use of an NCA compound prepared according to the process as defined above, or of an NCA compound as defined below, in the preparation of a polypeptide, an oligopeptide or a dendrimer.
- a seventh object of the present invention is a method for preparing a polypeptide, comprising a step of bringing into contact an NCA compound prepared according to the method as defined above, or an NCA compound as defined above above, with a polymerization initiator, chosen in particular from amines, in particular arginine.
- An eighth object of the present invention is a polypeptide, as obtained by the process for preparing a polypeptide as defined above.
- a ninth object of the present invention is a process for the preparation of an UNCA compound, comprising a step of bringing into contact an NCA compound prepared according to the process as defined above, or an NCA compound as defined above, with:
- a reagent allowing the introduction of a benzyloxycarbonyl protective group, chosen in particular from Cbz-Cl and Cbz-OSu, to obtain an UNCA compound protected on the nitrogen atom of the NCA cycle by a -Cbz group, • or a reagent making it possible to introduce a protective group fhiorényhnéthyloxycarbonyle, chosen in particular from Fmoc-Cl and Fmoc-OSu, to obtain an UNCA compound protected on the nitrogen atom of the NCA ring by an -Fmoc group.
- the starting NCA compound comprises an NCA ring in which the nitrogen atom is in the -NH form, making it possible to introduce a substituent.
- Figures 1 represent the analytical data obtained for the compound (L)Trp(Boc)-NCA of example 2.
- Figure 1A represents the NMR spectrum of the proton
- Figure 1B shows the LC chromatogram
- Figure 1C shows the mass spectrum
- Figures 2 represent an analysis by chiral HPLC on the diastereoisomers obtained according to example 22.
- Figure 2A represents the LC chromatogram of the racemic mixture
- Figure 2B represents the LC chromatogram of the diastereoisomer S, S, and
- Figure 2C shows the LC chromatogram of the R,S diastereoisomer.
- the LC/MS analyzes were carried out using a reversed phase Chromolith Flash 25 x 4.6 mm C 18 column. A flow rate of 3 ml/min and a gradient of (0 to 100%) of B on 2.5 min was used. Eluent A: water/0.1% HCO 2 H; eluent B: acetonitrile/0.1% HCO 2 H. UV detection was carried out at 214 nm. Electrospray mass spectra were acquired at a solvent flow rate of 200 ⁇ L/min. Nitrogen was used for both nebulizing and drying gas. Data was obtained in a scan mode ranging from 100 to 1000 m/z or 250 to 1500 m/z at 0.7 s intervals.
- Example 1 General procedure for the synthesis of NCAs compounds - in the presence of pyridine
- Boc-AA-OH (1 eq), was dissolved in ethyl acetate or dimethylformamide. Pyridine (3 eq) was added, followed by T3P® /Ac0Et 50% (2 eq), drop by drop. The reaction mixture was stirred at room temperature for 2 hours, and the progress of the reaction was analyzed by HPLC and LC/MS. The reaction mixture was diluted in ethyl acetate and washed twice with cold water, then with saturated aqueous NaCl solution. The organic phase was dried over anhydrous magnesium sulphate, filtered and concentrated under vacuum. The expected product was purified by recrystallization.
- Boc-(L)leu-OH (10g) was dissolved in ethyl acetate (300ml). T 3 P ® (2 equivalents), in solution in ethyl acetate was added dropwise, followed by pyridine (3 equivalents). The reaction mixture was stirred for 1 hour at room temperature. Water/ice (300 ml) was added, and the organic phase was recovered, washed twice with a cooled saturated aqueous NaCl solution (2 ⁇ 300 ml), dried over MgSO 4 , filtered and concentrated under vacuum. Hexane (50 mL) was added to the oily residue, causing crystallization.
- Boc-(L)Phe-OH (20g) was dissolved in ethyl acetate (1500ml). T 3 P ® (2 equivalents), in solution in ethyl acetate was added dropwise, followed by pyridine (3 equivalents). The reaction mixture was stirred for 1 hour at room temperature. Water/ice (1000 ml) was added, and the organic phase was recovered, washed twice with a cooled saturated aqueous NaCl solution (2 ⁇ 500 ml), dried over MgSO 4 . filtered and concentrated under vacuum. Hexane (100 mL) was added to the oily residue, causing crystallization.
- Boc-(L)Glu(OBzl)-OH 25g was dissolved in ethyl acetate (1500ml). T 3 P ® (2 equivalents), in solution in ethyl acetate was added dropwise, followed by pyridine (3 equivalents). The reaction mixture was stirred for 1 hour at room temperature. Water/ice (1000 ml) was added, and the organic phase was recovered, washed twice with a cooled saturated aqueous NaCl solution (2 ⁇ 500 ml), dried over MgSO 4 , filtered and concentrated under vacuum. Hexane (100 mL) was added to the oily residue, causing crystallization.
- Boc-(L)Lys-(Boc)-OH (10g) was dissolved in ethyl acetate (300ml). T 3 P ® (2 equivalents), in solution in ethyl acetate was added dropwise, followed by pyridine (3 equivalents). The reaction mixture was stirred for 1 hour at room temperature. Water/ice (300 ml) was added, and the organic phase was recovered, washed twice with a cooled saturated aqueous NaCl solution (2 ⁇ 300 ml), dried over MgSO 4 , filtered and concentrated under vacuum. Hexane (50 mL) was added to the oily residue, causing crystallization. The expected product was recrystallized from an AcOEt/hexane mixture to obtain (L)Lys-(Boc)-NCA (6.3g), which was stored under argon at -20°C. Yield 80%.
- Example 1 The general procedure of Example 1 was used, replacing the pyridine with the bases Et 3 N, iPr 2 EtN or DBU. After 2 hours of stirring at ambient temperature in ethyl acetate, the expected NCA product has formed predominantly, as analyzed by LC. 3 DBU 63
- Boc-(L)-Arg(Pbf)-OH (1 eq) was dissolved in ethyl acetate or dimethylformamide.
- the reaction mixture was stirred at 70°C for 2 hours, and the progress of the reaction was analyzed by HPLC and LC/MS.
- the reaction mixture was diluted in ethyl acetate and washed twice with cold water, then with saturated aqueous NaCl solution. The organic phase was dried over anhydrous magnesium sulphate, filtered and concentrated under vacuum. The expected product was purified by recrystallization.
- the purpose of this test is to confirm that the process according to the present invention is not racemizing and makes it possible to isolate the NCAs compounds with retention of the enantiomeric excess.
- the compounds (L)Asp(OBzl)-NCA and (D)Asp(OBzl)-NCA were prepared according to the procedure of Example 1, from Boc-(L)Asp(OBzl)-OH and Boc (D)Asp(OBzl)-OH respectively. Dimethylformamide was used as reaction solvent.
- NCAs compounds thus obtained were then reacted with (S)-1-(4-methoxyphenyl)ethan-1-amine to obtain the S,S and R,S diastereoisomers.
- Figure 2 shows the chromatograms thus obtained. A single peak was observed in both cases ( Figures 2B and 2C), confirming the retention of stereochemistry during the process. This result was also confirmed by 1 H-NMR analysis of the S,S and R,S diastereoisomers.
- Example 23 Comparative example - DCC versus T 3 P ®
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2014040A FR3118035A1 (fr) | 2020-12-23 | 2020-12-23 | Nouveau procédé de synthèse de composés NCAs |
| PCT/EP2021/086981 WO2022136366A1 (fr) | 2020-12-23 | 2021-12-21 | Nouveau procédé de synthèse de composés ncas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4267557A1 true EP4267557A1 (fr) | 2023-11-01 |
Family
ID=75438935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21839577.0A Withdrawn EP4267557A1 (fr) | 2020-12-23 | 2021-12-21 | Nouveau procédé de synthèse de composés ncas |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240109875A1 (fr) |
| EP (1) | EP4267557A1 (fr) |
| FR (1) | FR3118035A1 (fr) |
| WO (1) | WO2022136366A1 (fr) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3951741A (en) * | 1973-07-10 | 1976-04-20 | Peter Pfaender | Process and apparatus for the synthesis of peptides by use of n-carboxyanhydrides |
| DE2901843A1 (de) * | 1979-01-18 | 1980-07-31 | Hoechst Ag | Verfahren zur herstellung von carbonsaeureamiden und peptiden |
| NL1015169C2 (nl) * | 2000-05-12 | 2001-11-13 | Dsm Nv | Werkwijze voor de bereiding van N-carboxy-t-leucineanhydride. |
| US7829709B1 (en) * | 2007-08-10 | 2010-11-09 | Marquette University | Cysteine prodrugs to treat schizophrenia and drug addiction |
| FR3016879A1 (fr) * | 2014-01-29 | 2015-07-31 | Guillaume Laconde | Procede de preparation de benzotriazole n-acyles |
| WO2018042060A1 (fr) * | 2016-09-05 | 2018-03-08 | Drei Lilien Pvg Gmbh & Co. Kg | Membrane à pores ouverts dotée d'un réseau structural polymère interne s'étendant dans l'espace, destinée à la séparation sélective en matière par voie électrophorétique, ainsi que procédé de fabrication et utilisation |
-
2020
- 2020-12-23 FR FR2014040A patent/FR3118035A1/fr active Pending
-
2021
- 2021-12-21 US US18/259,089 patent/US20240109875A1/en active Pending
- 2021-12-21 EP EP21839577.0A patent/EP4267557A1/fr not_active Withdrawn
- 2021-12-21 WO PCT/EP2021/086981 patent/WO2022136366A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022136366A1 (fr) | 2022-06-30 |
| FR3118035A1 (fr) | 2022-06-24 |
| US20240109875A1 (en) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1201659B1 (fr) | Procédé de préparation des N-carboxyanhydrides | |
| JP4803352B2 (ja) | アミノ酸−n−カルボキシ無水物の製造方法 | |
| EP3924330A1 (fr) | Procédé de préparation d'un promédicament don à partir d'acide l-glutamique | |
| CA2387464C (fr) | Procede de preparation des n-carboxyanhydrides | |
| EP4267557A1 (fr) | Nouveau procédé de synthèse de composés ncas | |
| EP2139910B1 (fr) | Procede de synthese de peptides sans solvant | |
| EP0154581B1 (fr) | Nouveaux carbonates alpha-chlorés, leur procédé de fabrication et leur application à la protection des fonctions amines des amino-acides | |
| EP4527846A1 (fr) | Peptide étendu à deux résidus et son procédé de production | |
| CN1122026C (zh) | 羰基二咪唑,由其衍生的酯及它们的制备 | |
| BE1007184A3 (fr) | Procede de preparation d'un amide d'alpha-aminoacide, utilisable en synthese peptidique. | |
| EP0318338B1 (fr) | Procédé de préparation de synthons peptidiques | |
| CN104364229B (zh) | 通过使用氨基酸的邓盐合成二酰胺基胶凝剂 | |
| JP4852282B2 (ja) | N−カルボン酸無水物の製造方法 | |
| CA2694320C (fr) | Procede de fabrication d'un derive de n-(halopropyl)amino acide optiquement actif | |
| FR2858976A1 (fr) | Procede d'obtention de n-carboxyanhydrides d'alpha-aminoacides a protection urethane | |
| FR2616784A1 (fr) | Composes guanidiniques comprenant un ion tetraphenylborate, procede d'obtention de ces composes et utilisation des composes lors de la synthese peptidique | |
| FR2805811A1 (fr) | Urethane n-carboxyanhydrides issus de beta-aminoacides, leur procede de preparation et leurs utilisations | |
| KR20250141141A (ko) | 말레이미드기를 갖는 아민 염산염 및 그 제조 방법 | |
| FR2666086A1 (fr) | Fluorures d'acides amines et leur utilisation pour la preparation des peptides. | |
| FR2559767A1 (fr) | Procede de fabrication d'amino-acide a fonction amine protegee | |
| JP2024117554A (ja) | 新規脱水縮合剤 | |
| FR2589860A1 (fr) | Nouveau procede de preparation des n-nitrosourees | |
| FR2585354A1 (fr) | Procede stereoselectif de preparation de derives de la proline | |
| WO2019066578A1 (fr) | Procédé de préparation d'un composé intermédiaire pour une synthèse pharmaceutique | |
| CH688149A5 (fr) | Procédé de synthèse de 1-alkyl-3-hydroxy-5-halogéno-1,2,4-triazoles et nouveaux dérivés d'hydrazine. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230615 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Owner name: UNIVERSITE DE MONTPELLIER (UM) Owner name: ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER (ENSCM) |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20250701 |